Public Employees Retirement Association of Colorado Increases Holdings in Pacira Biosciences Inc (NASDAQ:PCRX)

Public Employees Retirement Association of Colorado lifted its position in Pacira Biosciences Inc (NASDAQ:PCRX) by 12.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 425,660 shares of the company’s stock after purchasing an additional 45,447 shares during the period. Public Employees Retirement Association of Colorado owned 1.03% of Pacira Biosciences worth $18,512,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC purchased a new stake in Pacira Biosciences during the second quarter worth $71,000. Amundi Pioneer Asset Management Inc. purchased a new stake in Pacira Biosciences during the first quarter worth $65,000. First Mercantile Trust Co. purchased a new stake in Pacira Biosciences during the first quarter worth $142,000. Convergence Investment Partners LLC purchased a new stake in Pacira Biosciences during the second quarter worth $174,000. Finally, Quantamental Technologies LLC purchased a new stake in Pacira Biosciences during the first quarter worth $162,000. Institutional investors own 99.89% of the company’s stock.

Shares of PCRX stock traded down $0.90 during trading hours on Wednesday, reaching $39.24. 9,224 shares of the company’s stock were exchanged, compared to its average volume of 584,574. The business’s 50 day moving average price is $42.49. The stock has a market cap of $1.75 billion, a P/E ratio of 134.33, a price-to-earnings-growth ratio of 1.61 and a beta of 1.15. The company has a current ratio of 8.62, a quick ratio of 7.83 and a debt-to-equity ratio of 0.99. Pacira Biosciences Inc has a fifty-two week low of $35.07 and a fifty-two week high of $55.00.

Pacira Biosciences (NASDAQ:PCRX) last released its earnings results on Thursday, August 8th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.27. Pacira Biosciences had a return on equity of 8.79% and a net margin of 2.04%. The firm had revenue of $102.60 million for the quarter, compared to the consensus estimate of $99.92 million. During the same period in the prior year, the firm earned $0.24 EPS. The firm’s revenue was up 22.0% on a year-over-year basis. On average, equities research analysts forecast that Pacira Biosciences Inc will post 0.76 EPS for the current fiscal year.

In related news, VP Lauren Bullaro Riker sold 2,126 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $44.28, for a total value of $94,139.28. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $444,659.76. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Charles A. Reinhart III sold 1,106 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $42.91, for a total value of $47,458.46. Following the completion of the transaction, the chief financial officer now directly owns 11,936 shares in the company, valued at $512,173.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,990 shares of company stock worth $2,497,045. 5.80% of the stock is owned by insiders.

A number of analysts have weighed in on PCRX shares. Wedbush set a $85.00 target price on Pacira Biosciences and gave the stock a “buy” rating in a report on Friday, June 28th. BidaskClub upgraded Pacira Biosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 31st. Zacks Investment Research upgraded Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 target price for the company in a report on Friday, August 2nd. Stifel Nicolaus set a $42.00 target price on Pacira Biosciences and gave the stock a “hold” rating in a report on Friday, August 9th. Finally, Barclays initiated coverage on Pacira Biosciences in a report on Tuesday, June 11th. They set an “overweight” rating and a $52.00 target price for the company. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the stock. Pacira Biosciences presently has an average rating of “Hold” and a consensus target price of $54.13.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Further Reading: Sell-Side Analysts

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Biosciences Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit